131 related articles for article (PubMed ID: 37470570)
1. Cisplatin-based combination therapy for cancer.
Minerva ; Bhat A; Verma S; Chander G; Jamwal RS; Sharma B; Bhat A; Katyal T; Kumar R; Shah R
J Cancer Res Ther; 2023; 19(3):530-536. PubMed ID: 37470570
[TBL] [Abstract][Full Text] [Related]
2. C-Jun N-terminal kinase signalling pathway in response to cisplatin.
Yan D; An G; Kuo MT
J Cell Mol Med; 2016 Nov; 20(11):2013-2019. PubMed ID: 27374471
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol improves sperm parameter and testicular apoptosis in cisplatin-treated rats: Effects on ERK1/2, JNK, and Akt pathways.
Shati AA
Syst Biol Reprod Med; 2019 Jun; 65(3):236-249. PubMed ID: 30507263
[TBL] [Abstract][Full Text] [Related]
4. Peroxiredoxin I plays a protective role against cisplatin cytotoxicity through mitogen activated kinase signals.
Ma D; Warabi E; Yanagawa T; Kimura S; Harada H; Yamagata K; Ishii T
Oral Oncol; 2009 Dec; 45(12):1037-43. PubMed ID: 19692293
[TBL] [Abstract][Full Text] [Related]
5. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells.
Zhang P; Liu SS; Ngan HY
PLoS One; 2012; 7(8):e42985. PubMed ID: 22900074
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin in cancer therapy: molecular mechanisms of action.
Dasari S; Tchounwou PB
Eur J Pharmacol; 2014 Oct; 740():364-78. PubMed ID: 25058905
[TBL] [Abstract][Full Text] [Related]
7. Late activation of stress-activated protein kinases/c-Jun N-terminal kinases triggered by cisplatin-induced DNA damage in repair-defective cells.
Helbig L; Damrot J; Hülsenbeck J; Köberle B; Brozovic A; Osmak M; Fiket Z; Kaina B; Fritz G
J Biol Chem; 2011 Apr; 286(15):12991-3001. PubMed ID: 21324906
[TBL] [Abstract][Full Text] [Related]
8. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.
Brozovic A; Fritz G; Christmann M; Zisowsky J; Jaehde U; Osmak M; Kaina B
Int J Cancer; 2004 Dec; 112(6):974-85. PubMed ID: 15386344
[TBL] [Abstract][Full Text] [Related]
9. Fenofibrate reduces cisplatin-induced apoptosis of renal proximal tubular cells via inhibition of JNK and p38 pathways.
Thongnuanjan P; Soodvilai S; Chatsudthipong V; Soodvilai S
J Toxicol Sci; 2016; 41(3):339-49. PubMed ID: 27193727
[TBL] [Abstract][Full Text] [Related]
10. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.
Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
Mol Pharmacol; 2004 Jan; 65(1):235-43. PubMed ID: 14722256
[TBL] [Abstract][Full Text] [Related]
11. Pro-apoptotic functions of TRAF2 in p53-mediated apoptosis induced by cisplatin.
Tsuchida M; Yokosawa T; Noguchi T; Shimada T; Yamada M; Sekiguchi Y; Hirata Y; Matsuzawa A
J Toxicol Sci; 2020; 45(4):219-226. PubMed ID: 32238696
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells.
Xu L; Fu Y; Li Y; Han X
Cancer Chemother Pharmacol; 2017 Aug; 80(2):235-242. PubMed ID: 28597042
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.
Persons DL; Yazlovitskaya EM; Cui W; Pelling JC
Clin Cancer Res; 1999 May; 5(5):1007-14. PubMed ID: 10353733
[TBL] [Abstract][Full Text] [Related]
14. Multiple Targets of 3-Dehydroxyceanothetric Acid 2-Methyl Ester to Protect Against Cisplatin-Induced Cytotoxicity in Kidney Epithelial LLC-PK1 Cells.
Lee D; Kim KH; Lee WY; Kim CE; Sung SH; Kang KB; Kang KS
Molecules; 2019 Mar; 24(5):. PubMed ID: 30832267
[TBL] [Abstract][Full Text] [Related]
15. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.
Mansouri A; Ridgway LD; Korapati AL; Zhang Q; Tian L; Wang Y; Siddik ZH; Mills GB; Claret FX
J Biol Chem; 2003 May; 278(21):19245-56. PubMed ID: 12637505
[TBL] [Abstract][Full Text] [Related]
16. Conditional expression of MAP kinase phosphatase-2 protects against genotoxic stress-induced apoptosis by binding and selective dephosphorylation of nuclear activated c-jun N-terminal kinase.
Cadalbert L; Sloss CM; Cameron P; Plevin R
Cell Signal; 2005 Oct; 17(10):1254-64. PubMed ID: 16038800
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review).
Wang G; Reed E; Li QQ
Oncol Rep; 2004 Nov; 12(5):955-65. PubMed ID: 15492778
[TBL] [Abstract][Full Text] [Related]
18. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin.
Nehmé A; Baskaran R; Aebi S; Fink D; Nebel S; Cenni B; Wang JY; Howell SB; Christen RD
Cancer Res; 1997 Aug; 57(15):3253-7. PubMed ID: 9242457
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin: The first metal based anticancer drug.
Ghosh S
Bioorg Chem; 2019 Jul; 88():102925. PubMed ID: 31003078
[TBL] [Abstract][Full Text] [Related]
20. Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines.
Watanabe J; Nishiyama H; Matsui Y; Ito M; Kawanishi H; Kamoto T; Ogawa O
Oncogene; 2006 Apr; 25(17):2500-8. PubMed ID: 16518417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
